Q-omics provides the consensus-scored SATB1 profile across patient tissues and cancer cell-line models. SATB1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SATB1 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, SATB1 RNA expression shows 20,479 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, LUAD, and KIRP as cancer lineages where SATB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SATB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SATB1 survival associations across molecular data types. SATB1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SATB1 RNA expression–survival associations across cancer types. High SATB1 expression shows favorable associations in UVM, SKCM, HNSC, BLCA, LGG and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SATB1 RNA expression.
This table summarizes SATB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SATB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SATB1 shows lower tumor expression in LUAD, BLCA, LUSC, KIRC, LIHC and HNSC. The LUAD box plot shows higher SATB1 RNA expression in normal versus tumor tissue (log2 FC = −1.038, t-test p < 0.001).
This table shows molecular features associated with SATB1 in patient tissues and cancer cell lines. In patient samples, SATB1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SATB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
